Explore 3 Stock Ideas & Industry Insights Download Free Report
The rally has become a major talking point acrossInvestmentplatforms and social media, where investors are debating whether the business has reached a turning point under its newLeadershipteam. With the share count now at nearly 981 million following monthly option exercises, the company'sMarket Valuehas climbed …
With the final weeks of the year approaching, the market is focused on two big questions: can OXB deliver within its revised 2026 range, and how much visibility does it have on the steep growth it is promising for 2027? Debate onInvestmentplatforms andSocial Mediahas …
The FTSE 250 trust has become a talking point among investors looking for exposure to the global healthcare sector, which has rebounded after a difficult period of pressure from drug pricing, tariffs and regulatory concerns. With the shares close to their 52-week high, investors …
The trust's half-year results, covering the six months to 30 September 2026, are expected shortly and will show how its portfolio has performed during the recovery.
The centralInvestmentquestions concernBusinessfundamentals, financial flexibility and how the development affects future performance.
The centralInvestmentquestions concern approval milestones, clinical evidence and how the development affects future performance.
The centralInvestmentquestions concernBusinessfundamentals, financial flexibility and how the development affects future performance.
The centralInvestmentquestions concern profit quality, segment margins and how the development affects future performance.
The centralInvestmentquestions concern dilution, funding flexibility and how the development affects future performance.
AstraZeneca Plc shares rose 0.75% to around 13,964.0p today, a gain of 104.00p, according to the supplied market data.
We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.
These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.
We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.
These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Download Free Report
Hi! How can we help you today?
Loading…